动态路径分析用于探索临床试验中的治疗效果调解过程,具有时间到事件终点
Matthias Kormaksson1, Markus Reiner Lange1, David Demanse1
1Analytics, Development, Novartis Pharma AG, Basel, Switzerland.
Statistics in medicine
|August 7, 2024
概括
动态路径分析解释了为什么生物标志物改善并不总是导致癌症治疗中的生存益处. 这种方法分解了治疗效应,为时间到事件的结果提供了对药物开发的见解.
科学领域:
- 生物统计学 生物统计学
- 临床试验方法论 临床试验方法论
- 药物指标 (Pharmacometrics) 是一个指标.
背景情况:
- 纵向生物标志物经常预测存活率,但它们的治疗效果可能不会改善整体存活率.
- 这种悖论需要先进的分析方法来理解治疗对生存结果的影响.
研究的目的:
- 介绍和详细介绍动态路径分析框架,用于用纵向介质和生存结果进行调解分析.
- 将总治疗效应分解为随时间的直接和间接影响.
主要方法:
- 动态路径分析的应用,一种调解分析技术.
- 对纵向介质数据和时间到事件生存数据的分析.
- 处理效应的分解成直接和间接的组成部分,随着时间的推移而演变.
主要成果:
- 证明了动态路径分析在解决生物标志物改善而没有生存益处的悖论中的实用性.
- 用模拟和真实瘤数据说明了该方法的应用.
- 通过时间依赖的效果演变,提供了对治疗效果的机制性见解.
结论:
- 动态路径分析为药物开发中的生存介导分析提供了一个强大的框架.
- 该方法提高了对治疗效果的理解,当时间到事件是主要结果时.
- 适用于临床研究中的各种场景,涉及纵向介质和生存终点.
更多相关视频
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
14.4K
10:26Problem-Solving Before Instruction PS-I: A Protocol for Assessment and Intervention in Students with Different Abilities
Published on: September 11, 2021
3.9K
相关概念视频
Comparing the Survival Analysis of Two or More Groups
166
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
166
Introduction To Survival Analysis
201
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
201
Hazard Ratio
106
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
106
Kaplan-Meier Approach
115
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
115
Assumptions of Survival Analysis
114
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
114
Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
